OP0205 April induces a novel subset of iga+ regulatory b cells that suppress inflammation through the expression of il-10 and pd-l1. (12th June 2018)
- Record Type:
- Journal Article
- Title:
- OP0205 April induces a novel subset of iga+ regulatory b cells that suppress inflammation through the expression of il-10 and pd-l1. (12th June 2018)
- Main Title:
- OP0205 April induces a novel subset of iga+ regulatory b cells that suppress inflammation through the expression of il-10 and pd-l1
- Authors:
- Fehres, C.
van Uden, N.
Yeremenko, N.
Fernandez, L.
Franco Salinas, G.
van Duivenvoorde, L.
Huard, B.
Morel, J.
Spits, H.
Hahne, M.
Baeten, D. - Abstract:
- Abstract : Background: Regulatory B cells (Bregs) are immunosuppressive cells that modulate immune responses through multiple mechanisms, such as the production of IL-10 and the skewing of T cell differentiation in favour of a regulatory phenotype. However, the signals required for the differentiation and activation of these cells remain still poorly understood. We have already shown that overexpression of the TNF family member A PRoliferation-Inducing Ligand (APRIL) reduces the incidence and severity of collagen-induced arthritis (CIA) in mice. Objectives: As we have also found that APRIL promoted IL-10 production and regulatory functions in human B cells, we hypothesised that APRIL, but not BAFF, may be involved in the induction and/or activation of IL-10 producing Bregs that suppress inflammatory responses in vitro and in vivo . Methods: Peripheral blood-derived naïve B cells were cultured in the presence of IL-21 +TGF-β, IL-21 +APRIL or IL-21 +BAFF to induce class switch recombination to IgA. Regulatory B cell functions and phenotypes were assessed on the class switched IgA B cells. Results: We describe that APRIL promotes the differentiation of naïve human B cells to IL-10-producing IgA + B cells. These APRIL-induced IgA + B cells display a regulatory B cell phenotype and inhibit T cell and macrophage responses in vitro through expression of IL-10 and PD-L1. Moreover, APRIL-induced IL-10 producing regulatory B cells suppress inflammation in vivo in experimentalAbstract : Background: Regulatory B cells (Bregs) are immunosuppressive cells that modulate immune responses through multiple mechanisms, such as the production of IL-10 and the skewing of T cell differentiation in favour of a regulatory phenotype. However, the signals required for the differentiation and activation of these cells remain still poorly understood. We have already shown that overexpression of the TNF family member A PRoliferation-Inducing Ligand (APRIL) reduces the incidence and severity of collagen-induced arthritis (CIA) in mice. Objectives: As we have also found that APRIL promoted IL-10 production and regulatory functions in human B cells, we hypothesised that APRIL, but not BAFF, may be involved in the induction and/or activation of IL-10 producing Bregs that suppress inflammatory responses in vitro and in vivo . Methods: Peripheral blood-derived naïve B cells were cultured in the presence of IL-21 +TGF-β, IL-21 +APRIL or IL-21 +BAFF to induce class switch recombination to IgA. Regulatory B cell functions and phenotypes were assessed on the class switched IgA B cells. Results: We describe that APRIL promotes the differentiation of naïve human B cells to IL-10-producing IgA + B cells. These APRIL-induced IgA + B cells display a regulatory B cell phenotype and inhibit T cell and macrophage responses in vitro through expression of IL-10 and PD-L1. Moreover, APRIL-induced IL-10 producing regulatory B cells suppress inflammation in vivo in experimental autoimmune encephalitis (EAE) and contact hypersensitivity (CHS) models. Finally, we showed a strong correlation between APRIL and IL-10 in the inflamed synovial tissue of inflammatory arthritis patients. Conclusions: We identified a novel subset of regulatory B cells within the IgA switched B cell population that suppresses inflammation in vitro and in vivo, which indicate the potential relevance of this subset of B cells for immune homeostasis and immunopathology. Disclosure of Interest: C. Fehres: None declared, N. van Uden: None declared, N. Yeremenko: None declared, L. Fernandez: None declared, G. Franco Salinas: None declared, L. van Duivenvoorde: None declared, B. Huard: None declared, J. Morel: None declared, H. Spits Shareholder of: AIMM Therapeutics., M. Hahne: None declared, D. Baeten: None declared … (more)
- Is Part Of:
- Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
- Journal:
- Annals of the rheumatic diseases
- Issue:
- Volume 77(2018)Supplement 2
- Issue Display:
- Volume 77, Issue 2 (2018)
- Year:
- 2018
- Volume:
- 77
- Issue:
- 2
- Issue Sort Value:
- 2018-0077-0002-0000
- Page Start:
- 151
- Page End:
- 152
- Publication Date:
- 2018-06-12
- Subjects:
- Rheumatism -- Periodicals
616.723005 - Journal URLs:
- http://ard.bmjjournals.com/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=149&action=archive ↗
http://www.bmj.com/archive ↗
http://gateway.ovid.com/server3/ovidweb.cgi?T=JS&MODE=ovid&D=ovft&PAGE=titles&SEARCH=annals+of+the+rheumatic+diseases.tj&NEWS=N ↗ - DOI:
- 10.1136/annrheumdis-2018-eular.3715 ↗
- Languages:
- English
- ISSNs:
- 0003-4967
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19890.xml